PKC Epsilon in Vascular Dysfunction

PKC Epsilon 在血管功能障碍中的应用

• 批准号: 8329950
• 负责人: Wei Zhou
• 金额: --
• 依托单位: VETERANS ADMIN PALO ALTO HEALTH CARE SYS
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-07-01 至 2016-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8329950
• 关键词: Acute; Animal Model; Atherosclerosis; Binding; Blood Vessels; Cardiovascular Diseases; Cardiovascular system; Carotid Artery Plaques; Cause of Death; Cell model; Cells; Cellular Stress; Clinical; Clinical Research; Coculture Techniques; Complication; Critical Pathways; Developed Countries; Diabetes Mellitus; Disease; Disease Progression; Distress; Etiology; Foundations; Functional disorder; Goals; Heart Atrium; Human; Hyperplasia; Injury; Insulin; Insulin Resistance; Intervention; Investigation; Ischemia; Knowledge; Laboratories; Matrix Metalloproteinases; Mediating; Mitochondria; Mitogen-Activated Protein Kinases; Modeling; Molecular; Molecular Models; Mus; Myocardium; Outcome; Patients; Peptides; Population; Procedures; Process; Production; Proteomics; Rattus; Reactive Oxygen Species; Reperfusion Injury; Reperfusion Therapy; Research; Risk; Role; Signal Pathway; Smooth Muscle Myocytes; Solid; System; Therapeutic; Time; Tissues; Transgenic Organisms; Translating; Transplantation; aldehyde dehydrogenases; base; cardiovascular risk factor; cell injury; clinically relevant; diabetic; improved; in vivo; innovation; macrophage; molecular modeling; new therapeutic target; novel; novel therapeutics; protein kinase C epsilon; resistin; restenosis; treatment strategy

DESCRIPTION (provided by applicant): Atherosclerosis is the leading cause of death in the developed countries. Diabetes mellitus markedly increases the risk of atherosclerotic complications. Emerging evidence suggests that resistin, a novel adipokine implicated in insulin resistin, contributes to atherosclerotic disease and the poor interventional outcomes among diabetic population. We and others have shown that resistin significantly induces vascular smooth muscle cell (VSMC) dysfunction, a key step in intimal hyperplasia and restenosis. However, little is known about the underlying mechanisms and the treatment option is largely lacking. Recently, we demonstrated that the cellular effect of resistin was mediated by PKC-[. Our research team also showed that activating PKC-¿ protected against ischemia/reperfusion injury of transplanted myocardium and inhibiting PKC-¿ mitigated intimal hyperplasia in rat. Although therapeutically targeting PKC-¿ in the treatment of atherosclerotic complications is largely unknown. Based on our novel, seemingly controversial observations, we believe that the involvement of PKC-¿ in cardiovascular disease is a dynamic process. Acute activation of PKC-¿ protects against ischemia/reperfusion-induced cellular injuries whereas sustained inhibition of PKC-¿ following procedures can minimize resistin-induced intimal hyperplasia and restenosis. It is our fundamental hypothesis that time-specific PKC-¿ modulation reduces resistin-induced intimal hyperplasia and restenosis. To pursue this hypothesis, we propose a more comprehensive investigation to elucidate the molecular mechanisms, cellular effects, and in vivo influences of PKC-¿ modulation in resistin-exaggerated cellular stress following vascular injury. Three specific aims (SA) are proposed. SA 1: Determine the role of PKC-¿ in resistin-induced cellular effects. In this SA, we will first confirm our preliminary findings and determine time-specific PKC-¿ modulation in VSMC. We will then explore the modulating effect of PKC-¿ using a novel activated macrophage-VSMC co-culture system. Lastly, we will verify the effects of resistin and PKC-¿ modulation in ex vivo human carotid plaques. SA 2: Characterize the molecular mechanisms of PKC-¿-dependent resistin-induced cellular distress. Using a HCASMC model, we will study the involvement of PKC-¿ in resistin-induced ROS over-production in the SA2a. We will also expand our preliminary observation by examining time-specific PKC-¿ modulation in known resistin-induced signaling pathways in SA2b. Lastly, we will explore novel PKC-¿-dependent downstream signaling pathway(s) using an unbiased proteomics approach and determine whether a novel PKC-¿-mediated molecular interaction, mitochondria aldehyde dehydrogenase (ALDH2), is involved in resistin- induced cellular dysfunction (SA2c). SA 3: Evaluate the effects PKC-¿ on resistin-augmented post-injury intimal hyperplasia in a murine model. We will independently modulate PKC-¿ before atrial clamping and after vascular interventions to determine the in vivo effects of time-specific PKC-¿ modulation on resistin-exacerbated intimal hyperplasia using a transgenic murine model. The potential application of novel PKC-¿ specific peptide modulators at specific time points, justified by successful completion of our aims, represents a novel therapeutic option. Deciphering clinically-relevant mechanism(s) of intimal hyperplasia and ultimately translating these into a novel therapeutic strategy to suppress disease progression supports our long-term goal of minimizing complications of cardiovascular diseases and improving the clinical outcome of cardiovascular procedures.

描述（由申请人提供）： 动脉粥样硬化是发达国家死亡的主要原因。新出现的证据表明，抵抗素（一种与胰岛素抵抗素有关的新型脂肪因子）会导致动脉粥样硬化疾病和糖尿病人群的不良干预结果。等人表明抵抗素显着诱导血管平滑肌细胞（VSMC）功能障碍，这是内膜增生和再狭窄的关键步骤。然而，人们对其潜在机制知之甚少，而且缺乏治疗方案。最近，我们证明抵抗素的细胞作用是由 PKC-介导的。我们的研究小组还表明，激活 PKC-¿防止移植心肌缺血/再灌注损伤并抑制 PKC-¿尽管以 PKC-¿ 为治疗目标，但可减轻大鼠的内膜增生。在动脉粥样硬化并发症的治疗中很大程度上未知。根据我们新的、有争议的观察，我们认为 PKC-¿ 的参与。心血管疾病中 PKC-¿ 的急性激活是一个动态过程。防止缺血/再灌注引起的细胞损伤，同时持续抑制 PKC-¿以下程序可以最大限度地减少抵抗素诱导的内膜增生和再狭窄。我们的基本假设是时间特异性 PKC-¿调节减少抵抗素诱导的内膜增生和再狭窄为了实现这一假设，我们提出了更全面的研究来阐明 PKC-¿ 的分子机制、细胞效应和体内影响。提出了三个具体目标（SA）：确定 PKC-¿ 的作用。在抵抗素诱导的细胞效应中，我们将首先确认我们的初步发现并确定时间特异性 PKC-¿然后我们将探讨 PKC-¿ 的调节作用。最后，我们将验证抵抗素和 PKC-¿ 的效果。离体人颈动脉斑块的调节 SA 2：表征 PKC-¿ 的分子机制。使用 HCASMC 模型，我们将研究 PKC-¿ 的参与。我们还将通过检查特定时间的 PKC-¿ 来扩大我们的初步观察。最后，我们将探索新的 PKC-¿ -使用无偏蛋白质组学方法依赖下游信号通路并确定是否有新的 PKC-¿ -介导的分子相互作用，线粒体醛脱氢酶 (ALDH2)，参与抵抗素诱导的细胞功能障碍 (SA2c)：评估 PKC-¿关于小鼠模型中抵抗素增强的损伤后内膜增生，我们将独立调节 PKC-¿在心房钳夹之前和血管干预之后确定时间特异性 PKC-¿ 的体内效果使用转基因小鼠模型调节抵抗素加剧的内膜增生 新型 PKC-¿ 的潜在应用。在特定时间点使用特定的肽调节剂，通过成功完成我们的目标来证明，代表了一种新的治疗选择，破译内膜增生的临床相关机制，并最终将其转化为抑制疾病进展的新治疗策略，支持我们的长期研究。最大限度地减少心血管疾病并发症并改善心血管手术的临床结果的长期目标。